A Multicenter, Open-Label Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis]
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2016
At a glance
- Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 02 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2014 Planned End Date changed from 1 Dec 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.